Search: onr:"swepub:oai:lup.lub.lu.se:8cc6a8cd-c937-4cb9-9872-76cd085481a6" >
Serum insulinlike g...
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
-
Standal, T (author)
-
Borset, M (author)
-
Lenhoff, S (author)
-
show more...
-
Wisloff, F (author)
-
Stordal, B (author)
-
Sundan, A (author)
-
Waage, A (author)
-
Seidel, C (author)
-
- Turesson, Ingemar (author)
- Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine
-
- Westin, Jan (author)
- Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2002
- 2002
- English.
-
In: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 100:12, s. 3925-3929
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of prognosis. After 80 months of follow-up, myeloma patients with low levels (< 13 nM) of serum IGF-1 had not reached median survival. In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Standal, T
-
Borset, M
-
Lenhoff, S
-
Wisloff, F
-
Stordal, B
-
Sundan, A
-
show more...
-
Waage, A
-
Seidel, C
-
Turesson, Ingema ...
-
Westin, Jan
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood
- By the university
-
Lund University
-
Karolinska Institutet